Omega Therapeutics Inc (OMGA) - Total Assets
Based on the latest financial reports, Omega Therapeutics Inc (OMGA) holds total assets worth $152.73 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Omega Therapeutics Inc net assets for net asset value and shareholders' equity analysis.
Omega Therapeutics Inc - Total Assets Trend (2019–2023)
This chart illustrates how Omega Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Omega Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Omega Therapeutics Inc's total assets of $152.73 Million consist of 44.0% current assets and 56.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.5% |
| Accounts Receivable | $6.99 Million | 3.4% |
| Inventory | $303.00K | 0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Omega Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OMGA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Omega Therapeutics Inc's current assets represent 44.0% of total assets in 2023, an increase from 43.4% in 2019.
- Cash Position: Cash and equivalents constituted 33.5% of total assets in 2023, down from 37.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 3.4% of total assets.
Omega Therapeutics Inc Competitors by Total Assets
Key competitors of Omega Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Omega Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | 3.80 | 3.12 |
| Quick Ratio | 1.61 | 3.39 | 3.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.78 Million | $75.08 Million | $16.30 Million |
Omega Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Omega Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 40.0% |
| Total Assets | $204.37 Million |
| Market Capitalization | $2.69 Million USD |
Valuation Analysis
Below Book Valuation: The market values Omega Therapeutics Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Omega Therapeutics Inc's assets grew by 40.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Omega Therapeutics Inc (2019–2023)
The table below shows the annual total assets of Omega Therapeutics Inc from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $204.37 Million | +39.98% |
| 2022-12-31 | $146.00 Million | -37.43% |
| 2021-12-31 | $233.33 Million | +730.87% |
| 2020-12-31 | $28.08 Million | +358.87% |
| 2019-12-31 | $6.12 Million | -- |
About Omega Therapeutics Inc
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epig… Read more